Advertisement: Bradfield Centre mid
RealVNC mid banner careers
ARM Innovation Hub
Advertisement: Cambridge Network
Advertisement: Mogrify
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
Advertisement: RSM
Advertisement Cambridge China Centre
Advertisement EY mid banner
14 September, 2006 - 14:20 By Staff Reporter

Medivir spins out compound

Medivir AB and Epiphany Biosciences have signed a license agreement on MIV-606 (valomaciclovir), Phase II compound with potent activity against varicella zoster virus (VZV) and other viruses.Medivir will receive equity in Epiphany, milestone payments of up to $24.5m and royalty from worldwide sales except the Nordic countries where Medivir has retained the marketing rights.

Epiphany will be responsible for the further clinical development of MIV-606.

Phase IIa studies have shown MIV-606 to be efficacious and safe in patients with shingles, caused by the varicella zoster virus (VZV).

The market for zoster drugs is going to increase with the aging population according to the companies.

MIV-606 is also a potent inhibitor of other herpesviruses

increasingly imp-licated in various diseases such as mononucleosis, chronic fatigue syndrome, multiple sclerosis and the development of HIV/AIDS.

Medivir’s East of England headquarters is located at Chesterford Research Park in Essex.

Add new comment

Newsletter Subscription

Stay informed of the latest news and features